Photo Credit: Nemes Laszlo
The following is a summary of “Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition,” published in the March 2024 issue of Pulmonology by Saal et al.
In the realm of non-small cell lung cancer (NSCLC) treatment with immune checkpoint inhibition (ICI), a considerable subset of patients attains stable disease (SD) as their optimal response, yielding diverse outcomes. Addressing this heterogeneity necessitates the identification of supplementary biomarkers to refine outcome prediction. Building on previous research demonstrating the utility of the on-treatment modified Glasgow prognostic score (mGPS) – derived from C-reactive protein (CRP) and albumin levels – in enhancing outcome prediction in metastatic renal cell carcinoma, the researchers sought to explore its applicability in NSCLC patients on ICI.
Their investigation evaluated the prognostic and predictive potential of on-treatment mGPS at week six in NSCLC patients undergoing treatment with atezolizumab or docetaxel within the phase 3 OAK trial (NCT02008227; n = 750 patients), with validation conducted in the phase 2 BIRCH trial (NCT02031458; n = 560). Results indicated that on-treatment mGPS assessment at week six furnished valuable prognostic insights, with significant hazard ratios observed across risk categories in the atezolizumab-treated subgroup.
Furthermore, on-treatment mGPS outperformed RECIST imaging criteria in predicting overall survival, particularly notable in patients exhibiting SD. These findings, validated in the BIRCH trial, underscore the potential of integrating on-treatment mGPS alongside radiological imaging for refined outcome prediction in NSCLC patients undergoing ICI therapy.
Source: sciencedirect.com/science/article/pii/S0169500224000382